Abstract
ABSTRACTThe promise of gene therapy in chronic pain management is described. Use of the Herpes simplex virus to deliver such therapy is discussed. Clinical trials of gene-based therapy for neuropathic, cancer, and inflammatory pain are summarized. The potential role for such therapies are discussed.This feature is adapted from paineurope 2012; Issue 1, ©Haymarket Medical Publications Ltd., and is presented with permission. paineurope is provided as a service to pain management by Mundipharma International, Ltd., and is distributed free of charge to health care professionals in Europe. Archival issues can be accessed via the Web site: http://www.paineurope.com at which European health professionals can register online to receive copies of the quarterly publication.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
